- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Crisil Ratings has reaffirmed Neuland Labs' long-term credit rating at CRISIL A+, with its outlook revised to 'Positive'. This upgrade in outlook suggests an improving credit profile for the company. The short-term rating of CRISIL A1 has also been reaffirmed. This is a positive signal for investors regarding the company's...
Neuland Labs reported strong Q1FY27 financial results: total income rose 16.3% to INR650.1 Cr, EBITDA hit INR231.1 Cr (35.5% margin), and PAT reached INR147.4 Cr. This performance, driven by commercial CMS projects, aligns with management expectations for a good start to the year. The company's new peptide facility will commission...